Dissolution rates and supersaturation behavior of amorphous repaglinide particles produced by controlled precipitation

Journal of Biomedical Nanotechnology

Volumn 3, Issue 1, 2007, Pages 18-27

  Sinswat, Prapasri ^a   Matteucci, Michal E ^b   Johnston, Keith P ^b   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b The University of Texas at Austin   (United States)

Author keywords

Controlled precipitation; Dissolution; Polymers; Repaglinide; Supersaturation

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL; POLYMER; POLYVINYL ALCOHOL; POVIDONE; REPAGLINIDE;

CONFERENCE PAPER; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG CONCENTRATION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STORAGE; DRUG STRUCTURE; HYDROGEN BOND; IN VITRO STUDY; MISCIBILITY; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; THERMAL ANALYSIS; X RAY DIFFRACTION;

EID: 45849111476     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2007.001     Document Type: Conference Paper

References (43)

1. J. Kreuter, Peroral administration of nanoparticles. Adv. Drug Deliv. Rev. 7, 71 (1991).
2. R. H. Muller, C. Jacobs, and O. Kayser, Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3 (2001).
3. N. Hussain, V. Jaitley, and A. T. Florence, Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev. 50, 107 (2001).
4. C. A. Lipinski, Poor aqueous solubility - an industry wide problem in drug discovery. Am. Pharm. Rev. 5, 82 (2002).
5. C. Leuner and J. Dressman, Improving drug solubility for oral delivery using solid dispersions. Eur J. Pharm. Biopharm. 50, 47 (2000).
6. B. E. Rabinow, Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3, 785 (2004).
7. G. G. Liversidge and K. C. Cundy, Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolut oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125, 91 (1995).
8. T. L. Rogers, I. B. Gillespie, J. E. Hitt, K. L. Fransen, C. A. Crowl, C. J. Tucker, G. B. Kupperblatt, J. N. Becker, D. L. Wilson, C. Todd, and E. J. Elder, Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly water-soluble drugs. Pharm. Res. 21, 2048 (2004).
9. B. K. Johnson and R. K. Prud'homme, Engineering the direct precipitation of stabilized organic and block copolymer nanoparticles as unique composites. Poly. Mater Sci. Eng. 36, 744 (2003).
10. M. Nakano, Places of emulsions in drug delivery. Adv. Drug Deliv. Rev. 45, 1 (2000).
11. J. Hu, K. P. Johnston, and R. O. Williams III, Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev. Ind. Pharm. 30, 233 (2004).
12. V. J. Stella and R. A. Rajewski, Cyclodextrins: Their future in drug formulation and delivery. Pharm. Res. 14, 556 (1997).
13. M. M. Akers, Excipient-drug interactions in parenteral formulations. J. Pharm. Sci. 91, 2283 (2002).
14. R. Loftsson and M. E. Brewster, Pharmaceutical applications of cyclodextrins. J. Pharm. Sci. 85, 1017 (1996).
15. C. Leuner and J. Dressman, Improving drug solubility for oral delivery using solid dispersions. Eur J. Pharm. Biopharm. 50, 47 (2000).
16. B. C. Hancock and M. Parks, What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 17, 397 (2000).
17. A. A. Noyes and W. R. Whitney, The rate of solution of solid substances in their own solutions. J Am. Chem. Soc. 19, 930 (1897).
18. O. Sohnel and J. Garside. Precipitation: Basic Principles and Industrial Applications, Butterworth Heinemann (1992).
19. W. L. McCabe, J. C. Smith, and P. Harriott, Unit Operations of Chemical Engineering, McGraw-Hill, New York (2001).
20. S. L. Raghavan, A. Trividic, A. F. Davis, and J. Hadgraft, Effect of cellulose polymers on supersaturation and in vitro membrane tranport of hydrocortisone acetate. Int. J Pharm. 193, 231 (2000).
21. M. Iervolino, S. L. Raghavan, and J. Hadgraft, Membrane penetration enhancement of ibuprofen using supersaturation. Int. J Pharm. 198, 229 (2000).
22. M. Iervolino, B. Cappello, S. L. Raghavan, and J. Hadgraft, Penetration enhancement of ibuprofen from supersaturated solutions through human skin. Int. J. Pharm. 212, 131 (2001).
23. B. R. Jasti, B. Berner, S.-L. Zhou, and X. Li, A Novel method for determination of drug solubility in polymeric matrices. J. Pharm. Sci. 93, 2135 (2004).
24. K. Yamashita, T. Nakate, K. Okimoto, A. Ohike, Y. Tokunaga, R. Ibuki, K. Higaki, and T. Kimura, Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int. J Pharm. 267, 79 ( 2003).
25. K. Okimoto, M. Miyake, R. Ibuki, M. Yasumura, N. Ohnishi, and T. Nakai, Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypropylmethylcellulose. Int. J Pharm. 159, 85 (1997).
26. H. Suzuki and H. Sunada, Influence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers. Chem. Pharm. Bull. 46, 482 (1998).
27. S. L. Raghavan, A. Trividic, A. F. Davis, and J. Hadgraft, Crystallization of hydrocortisone acetate: Influence of polymers. Int. J. Pharm. 212, 213 (2001).
28. P. Gao, B. D. Rush, W. P. Pfund, T. Huang, J. M. Bauer, W. Morozowich, M.-S. Kuo, and M. J. Hageman, Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci. 92, 2386 (2003).
29. P Gao, M. E. Guyton, T. Huang, J. M. Bauer, K. J. Stefanski, and Q. Lu, Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev. Ind. Pharm. 30, 221 (2004).
30. C. Culy and B. Jarvis, Repaglinide, A review of its therapeutic use in Type 2 diabetes mellitus. Drugs 61, 1625 (2001).
31. W. Malaisse, Repaglinide, a new oral antidiabetic agent: A review of recent preclinical studies. Eur J. Clin. Invest. 29, 21 (1999).
32. V. Hatorp, S. Oliver, and C.-A. P. F. Su, Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. 36, 636 (1998).
33. T. C. Marbury, J. L. Ruckle, V. Hatorp, M. P. Andersen, K. K. Nielsen, W. C. Huang, and P. Strange, Pharmacokinetics of repaglinide in subjects with renal impairment. Clin. Pharmacol. Ther. 67, 7 (2000).
34. T. Marbury, W.-C. Huang, P. Strange, and H. Lebovitz, Repaglinide versus glyburide: A one-year comparison trial. Diabetes Res. Clin. Prac. 43, 155 (1999).
35. J. Hecq, M. Deleers, D. Fanara, H. Vranckx, and K. Amigbi, Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm. 299, 167 (2005).
36. P. Borm, F. C. Klaessig, T. D. Landry, B. Moudgil, J. Pauluhn, K. Thomas, R. Trottier, and S. Wood, Research strategies for safety evaluation of nanomaterials, Part V: Role of dissolution in biological fate and effects of nanoscale particles. Toxicol. Sci. 90, 23 ( 2006).
37. M. Gordon and J. S. Taylor, Ideal copolymers and the second order transition of synthetic rubbers 1. Non-crystalline co-polymers. J. Appl. Chem. 2, 493 (1952).
38. R. Simha and R. F. Boyer, General relation involving the glass transition temperature and coefficient of expansion of polymers. J. Chem. Phys. 37, 1003 (1962).
39. K. Tanaka, S. Kitamura, and T. Kitagawa, Effect of structural relaxation on the physical and aerosol properties of amorphous form of FK888 (NK1 antagonist). Chem. Pharm. Bull. 53, 498 (2005).
40. M. E. Matteucci, B. K. Brettmarm, R. O. Williams III, and K. P. Johnston, Stable supersaturated solutions of a poorly water soluble drug from amorphous nanoparticle dissolution in preparation. J. Control. Rel. (2006), submitted.
41. S. A. Mitchell, T. D. Reynolds, and T. P. Dasbach, A compaction process to enhance dissolution of poorly water-soluble drugs using hydroxypropyl methylcellulose. Int. J. Pharm. 250, 3 (2003).
42. J. M. Vaughn, J. T. McConville, M. T. Crisp, K. P. Johnston, and R. O. Williams III, Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies, Drug Dev. Ind. Pharm. 32, 559 (2006).
43. J. Hu, K. P. Johnston, and R. O. Williams III, Stable amorphous danazol nanostructured powders with rapid dissolution rates produced by spray freezing into liquid. Drug Dev. Ind. Pharm. 30, 695 (2004).